Ocular Therapeutix (NSDQ:OCUL) revealed last week that it received a subpoena from the Securities and Exchange Commission dated Dec. 15, requesting information about the company’s post-surgical pain relief implant, Dextenza, which was rejected by the FDA earlier this year.
The Bedford, Mass.-based company did not specify what the SEC was asking for, but noted that the request covers communications between Ocular Therapeutix and the FDA, as well as investors.
Get the full story at our sister site, Drug Delivery Business News.
The post SEC subpoenas Ocular Therapeutix over pain relief implant appeared first on MassDevice.
from MassDevice http://ift.tt/2kYJPo8
Cap comentari:
Publica un comentari a l'entrada